Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prediction of individual genetic risk to prostate cancer using a polygenic score

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Perinatal exposure to mixtures of anti-androgenic chemicals causes proliferative lesions in rat prostate

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PrognosticValue of PINP,BoneAlkaline Phosphatase, CTX-I, andYKL-40 in Patients With Metastatic Prostate Carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
BACKGROUND: The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients. PATIENTS AND METHODS: The uPAR forms were measured in samples from 131 metastatic PC patients. These constituted a subset of patients included in a randomized clinical trial of treatment with total androgen blockade (TAB) versus polyestradiol phosphate (PEP). Pre-treatment serum levels of intact uPAR (uPAR(I-III)), intact plus cleaved uPAR (uPAR(I-III) + uPAR(II-III)) and domain I (uPAR(I)) were measured using time-resolved fluorescence immunoassays (TR-FIAs). RESULTS: High serum levels of each of the uPAR forms were significantly associated with short overall survival (OS). The prognostic impact was strongest in the TAB treated patients with all uPAR forms being statistically significant. In multivariate analysis, uPAR(I-III) + uPAR(II-III) was an independent prognostic factor in TAB treated patients (HR = 5.2, 95% confidence interval (CI): 2.5-10.6, P 
Original languageEnglish
JournalProstate
Volume71
Issue number8
Pages (from-to)899-907
Number of pages9
ISSN0270-4137
DOIs
Publication statusPublished - 1 Jun 2011

    Research areas

  • Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Carcinoma, Estradiol, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Receptors, Urokinase Plasminogen Activator, Retrospective Studies, Treatment Outcome

ID: 31004883